Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ASLN |
---|---|---|
09:32 ET | 2010 | 0.419 |
09:34 ET | 805 | 0.428 |
09:45 ET | 1000 | 0.4289 |
10:01 ET | 321 | 0.425 |
10:03 ET | 2698 | 0.412 |
10:06 ET | 4187 | 0.4101 |
10:08 ET | 1850 | 0.41 |
10:10 ET | 100 | 0.42 |
10:14 ET | 3000 | 0.42044 |
10:26 ET | 903 | 0.42 |
10:37 ET | 200 | 0.424901 |
10:50 ET | 130 | 0.421 |
11:22 ET | 100 | 0.421 |
11:29 ET | 422 | 0.4288 |
11:31 ET | 3007 | 0.421 |
11:38 ET | 3000 | 0.4289 |
11:40 ET | 178 | 0.425 |
12:05 ET | 701 | 0.4251 |
12:18 ET | 200 | 0.425 |
12:45 ET | 2389 | 0.4255 |
12:50 ET | 5000 | 0.42525 |
12:59 ET | 312 | 0.4255 |
01:51 ET | 400 | 0.4251 |
02:18 ET | 11900 | 0.42 |
02:20 ET | 25388 | 0.42 |
02:27 ET | 2200 | 0.4195 |
02:29 ET | 2500 | 0.42 |
02:42 ET | 1100 | 0.42 |
02:49 ET | 170 | 0.42 |
03:00 ET | 200 | 0.42 |
03:07 ET | 300 | 0.42 |
03:18 ET | 662 | 0.4242 |
03:23 ET | 100 | 0.4289 |
03:56 ET | 290 | 0.4288 |
03:59 ET | 2547 | 0.428699 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Aslan Pharmaceuticals Ltd | 9.7M | -0.1x | --- |
Calidi Biotherapeutics Inc | 9.7M | -0.3x | --- |
Enzon Pharmaceuticals Inc | 9.6M | 43.6x | -60.21% |
NuCana PLC | 7.6M | 0.0x | --- |
Portage Biotech Inc | 9.5M | -0.1x | --- |
Vaxxinity Inc | 9.9M | -0.2x | --- |
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $9.7M |
---|---|
Revenue (TTM) | $12.0M |
Shares Outstanding | 905.1K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.45 |
EPS | $-3.01 |
Book Value | $3.00 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 0.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -369.02% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.